ustiloxin D: an antimitotic cyclic peptide; from false smut balls on rice panicles caused by Ustilaginoidea virens; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 157840 |
| CHEMBL ID | 386110 |
| CHEBI ID | 168103 |
| MeSH ID | M0235572 |
| Synonym |
|---|
| CHEBI:168103 |
| 158243-18-6 |
| 2-[[(3r,4s,7s,10s,11r)-3-ethyl-11,15-dihydroxy-3-methyl-10-(methylamino)-6,9-dioxo-7-propan-2-yl-2-oxa-5,8-diazabicyclo[10.3.1]hexadeca-1(15),12(16),13-triene-4-carbonyl]amino]acetic acid |
| ustiloxin d |
| CHEMBL386110 |
| glycine, threo-beta,3-dihydroxy-n-methyl-l-tyrosyl-l-valyl-3-hydroxy-l-isoleucyl-, cyclic (1(3)-3)-ether |
| glycine, (beta-r)-beta,3-dihydroxy-n-methyl-l-tyrosyl-l-valyl-3-hydroxy-l-isoleucyl-, cyclic (1(sup 3)-3)-ether |
| (beta-r)-beta,3-dihydroxy-n-methyl-l-tyrosyl-l-valyl-3-hydroxy-l-isoleucylglycine cyclic (1(sup 3)-3)-ether |
| DTXSID90166386 |
| Class | Description |
|---|---|
| oligopeptide | A peptide containing a relatively small number of amino acids. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Tubulin beta-4A chain | Homo sapiens (human) | IC50 (µMol) | 1.5000 | 0.0005 | 1.9680 | 10.0000 | AID270819 |
| Tubulin beta chain | Homo sapiens (human) | IC50 (µMol) | 1.5000 | 0.0005 | 2.0529 | 10.0000 | AID270819 |
| Tubulin alpha-3C chain | Homo sapiens (human) | IC50 (µMol) | 1.5000 | 0.0005 | 1.9555 | 10.0000 | AID270819 |
| Tubulin alpha-1B chain | Homo sapiens (human) | IC50 (µMol) | 1.5000 | 0.0005 | 1.9555 | 10.0000 | AID270819 |
| Tubulin alpha-4A chain | Homo sapiens (human) | IC50 (µMol) | 1.5000 | 0.0005 | 1.9555 | 10.0000 | AID270819 |
| Tubulin beta-4B chain | Homo sapiens (human) | IC50 (µMol) | 1.5000 | 0.0005 | 1.9680 | 10.0000 | AID270819 |
| Tubulin beta-3 chain | Homo sapiens (human) | IC50 (µMol) | 1.5000 | 0.0005 | 1.8945 | 10.0000 | AID270819 |
| Tubulin beta-2A chain | Homo sapiens (human) | IC50 (µMol) | 1.5000 | 0.0005 | 1.9680 | 10.0000 | AID270819 |
| Tubulin beta-8 chain | Homo sapiens (human) | IC50 (µMol) | 1.5000 | 0.0005 | 1.9680 | 10.0000 | AID270819 |
| Tubulin alpha-3E chain | Homo sapiens (human) | IC50 (µMol) | 1.5000 | 0.0005 | 1.9555 | 10.0000 | AID270819 |
| Tubulin alpha-1A chain | Homo sapiens (human) | IC50 (µMol) | 1.5000 | 0.0005 | 1.9555 | 10.0000 | AID270819 |
| Tubulin alpha-1C chain | Homo sapiens (human) | IC50 (µMol) | 1.5000 | 0.0005 | 1.9555 | 10.0000 | AID270819 |
| Tubulin beta-6 chain | Homo sapiens (human) | IC50 (µMol) | 1.5000 | 0.0005 | 1.9680 | 10.0000 | AID270819 |
| Tubulin beta-2B chain | Homo sapiens (human) | IC50 (µMol) | 1.5000 | 0.0005 | 1.9680 | 10.0000 | AID270819 |
| Tubulin beta-1 chain | Homo sapiens (human) | IC50 (µMol) | 1.5000 | 0.0005 | 1.9870 | 10.0000 | AID270819 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID270819 | Inhibition of tubulin polymerization | 2006 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18 | Total synthesis and biological evaluation of ustiloxin natural products and two analogs. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.78) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||